VivoSeq
Other

Weight Loss

90

Pipeline Programs↗

38

Active Trials↗

44

Companies Involved↗

Weight loss is a moderately active landscape with 90 programs across 44 companies. The most active players are GSK, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Regeneron. 17 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

43/100

Mech. Concentration

6/100

Completion Rate

74/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

2 programs

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

2 programs

Phase 1Regeneron logo

Regeneron

2 programs

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2N

Nastech Pharmaceutical Company, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical12

Semaglutide

Novo Nordisk

Celecoxib

Philadelphia Eye Associates

Acetaminophen

Kenvue Brands

Rosiglitazone

Alnylam Pharmaceuticals

Lorcaserin

Eisai

Phase 19

Phentermine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Nandrolone Decanoate

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

GSK189075

GSK

Mounjaro

Eli Lilly

Tetrahydrocannabivarin

Medical Life Care Planners, LLC

Phase 235

Olanzapine

MODAG GmbH

Testosterone Enanthate

Antares Pharma Inc.

Oxytocin

Retrophin

Mirtazapine

Organon and Co

Tranexamic Acid

Amring

Phase 317

Exenatide

AstraZeneca

Tirzepatide

Eli Lilly

Rimonabant

Sanofi

Cagrilintide

Novo Nordisk

Metformin

EMD Serono

Approved17

Midazolam

Conrado Roberto Hoffmann Filho

Rifaximin

Salix

Topiramate

Wim Janssens

Dapagliflozin

AstraZeneca

Liraglutide

Novo Nordisk

Analysis

Modality Breakdown

93%

Small molecule

97 of 104 classified programs — the dominant modality here.

7%ALL OTHERSPeptide55%Monoclonal antibody22%

Small molecule leads; the ring shows all 104 classified programs, each share of the total. Modality classified for 100% of 106 pipeline programs.

Analysis

Trial Status

156

clinical trials

Completed78 · 50%
Terminated21 · 13%
Recruiting16 · 10%
Unknown status12 · 8%
Active, not recruiting10 · 6%
Not yet recruiting10 · 6%
Other9 · 6%

Clinical Trials

Trial Activity

156 trials

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07292441·500 enrolled
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
Recruiting·UUniversity College Dublin·N/A·NCT04174755·80 enrolled
Comparison of Body Composition Changes With Weight Loss Interventions
Recruiting·VVanderbilt University Medical Center·N/A·NCT07115069·60 enrolled
Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss
Recruiting·—·Phase 1·NCT06734273·42 enrolled
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
Recruiting·PProf. Dr. Martin Wabitsch·N/A·NCT07302802·70 enrolled
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07184086·80 enrolled
Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT06998758·60 enrolled
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
Recruiting·UUniversity of Chicago·Phase 1·NCT06171152·30 enrolled
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Recruiting·—·Phase 4·NCT05919797·120 enrolled
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Recruiting·—·Phase 3·NCT07297290·220 enrolled
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Recruiting·AAgelessRx·Phase 2/3·NCT07092618·150 enrolled
Combining Chinese Medicine and Nutrition to Enhance Weight Loss After Bariatric Surgery
Recruiting·—·N/A·NCT06419764·120 enrolled
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
Recruiting·MMcMaster University·Phase 4·NCT06852391·74 enrolled
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
Recruiting·TThe Royal's Institute of Mental Health Research·Phase 4·NCT06809166·40 enrolled
This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control
Recruiting·GGeneral Committee of Teaching Hospitals and Institutes, Egypt·Phase 4·NCT06981936·150 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)